American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
    Meeting Abstract

    Winter, A. M.; Bharadwaj, S.; Herrera, A. F.; Iragavarapu, C.; Mirza, S.; Palomba, M. L.; Patel, S. S.; Gharibo, M. M.; Bernasconi, D.; Krimmel, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008
    Meeting Abstract

    Braunstein, L. Z.; Mitchell, M.; Bandos, H.; Sikov, W. M.; Khan, A. J.; Chen, P. Y.; Ganz, P. A.; Jagsi, R.; White, J. R.; Cecchini, R. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial
    Meeting Abstract

    Matar, S.; Jegede, O.; Denize, T.; Ghandour, F.; Laimon, Y. N.; El Ahmar, N.; Sheshdeh, A. B.; Savla, V.; Mohanna, R. A.; Catalano, P. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio-San-Simón, A.; Tornøe, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001
    Meeting Abstract

    Pal, S. K.; Medioni, J.; de Velasco, G.; Merchan, J. R.; Büchler, T.; Apolo, A. B.; Loriot, Y.; Wang, Z.; Jew, T.; Cao, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Wagner, A. J.; Trent, J. C.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study
    Meeting Abstract

    Iyer, S. P.; Jagadeesh, D.; Domingo-Domenech, E.; Benedetti, F.; Izquierdo, A. R.; Bouabdallah, K.; Vitolo, U.; Illidge, T. M.; Liu, J.; Shaikh, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis
    Meeting Abstract

    Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. K.; Hoering, A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save